Dimerix Ltd. engages in the investment of the research and development of biopharmaceutical drugs. The company is headquartered in Melbourne, Victoria. The firm is focused on developing lives of patients with inflammatory diseases, including both kidney and respiratory diseases. The company develops and commercializes patient preferred pharmaceutical products for global markets using its receptor technology to identify and develop drugs in areas with an unmet need. The firm is focused on developing its Phase III product candidate DMX-200 (QYTOVRA), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and is also developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its Receptor Heteromer Investigation Technology (Receptor-HIT) is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets.
Follow-Up Questions
Who is the CEO of Dimerix Ltd?
Dr. Nina Webster is the Chief Executive Officer of Dimerix Ltd, joining the firm since 2018.
What is the price performance of SBMJF stock?
The current price of SBMJF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Dimerix Ltd?
Dimerix Ltd belongs to Biotechnology industry and the sector is Health Care
